Amanda Mikels Vigdal
About Amanda Mikels Vigdal
Amanda Mikels Vigdal is a Senior Director at Bristol Myers Squibb in California, with extensive experience in oncology, immuno-oncology, and translational research.
Current Role at Bristol Myers Squibb
Amanda Mikels Vigdal is currently serving as Senior Director at Bristol Myers Squibb in California, United States. Her role involves overseeing various aspects of the company's strategic direction and management in oncology and immuno-oncology. She brings extensive experience in biological research and project leadership to her current position.
Previous Positions at Bristol Myers Squibb
Before her current role, Amanda held the position of Director Stromal Biology TME TRC at Bristol Myers Squibb, located in Redwood City, California, from 2020 to 2022. During her tenure, she focused on research and development in stromal biology towards tumor microenvironments, significantly contributing to the company's scientific advancements.
Career at Gilead Sciences
Amanda Mikels Vigdal served as a Senior Research Scientist at Gilead Sciences from 2011 to 2020. During her nine years at the company, she was involved in leading key research initiatives, particularly focusing on oncology and fibrosis. Her work at Gilead Sciences underscored her capabilities in the scientific research community.
Educational Background
Amanda earned her Doctor of Philosophy (PhD) in Oncology and Cancer Biology from Stanford University School of Medicine, where she studied from 2001 to 2007. Prior to that, she received her Bachelor of Science (B.S.) in Microbiology from UC San Diego, graduating in 2001. She also holds a high school diploma from Alta Loma High, where she studied from 1993 to 1997.
Scientific Leadership and Project Management
Throughout her career, Amanda has led project teams focused on novel targets in oncology and immuno-oncology, guiding them through various phases including target validation, lead identification, optimization, and pre-IND toxicology studies. She has also been the biology lead for antibody therapeutic programs targeting matrix proteins in fibrosis, inflammation, and cancer, showcasing her extensive project management capabilities.